Highly Potent Active Pharmaceuticals Ingredients

October 21-22, 2019 | USA

SMi is delighted to announce its Highly Potent Active Pharmaceutical Ingredients conference coming to Boston on the 21st - 22nd October 2019. The HPAPI global market is growing at an ever-increasing rate of CAGR at 8.6% that is projected to reach USD $31.56 Billion by 2025, with a significant segment market of HPAPI being oncology ADC which is at a CARG of a staggering 20%. The continual elevation of HPAPI potencies along with toxicity will further drive the needs for more cutting-edge containment solutions and best practices guidelines to ensure worker safety.

Spotlight

Each year lung cancer causes over 1.59 million deaths worldwide, more than any other cancer. Approximately 85% of lung cancer cases are a type of lung cancer called non-small cell lung cancer, and of these 5% are anaplastic lymphoma kinase (ALK)-positive. This type of lung cancer can be effectively targeted by a type of drug called an ALK-inhibitor, but how do they work?


OTHER PAST CONFERENCES

Medicinal Chemistry and Drug Design

July 4-5, 2022 | UK

Chemistry Conferences welcome chemical professionals, researchers, professors, scientific communities, delegates, students, business professionals and executives from all over the world to attend the “22nd World Congress on Medicinal Chemistry and Drug Design” which is to be held during July 04-05, 2022 Aberdeen, UK.

International Conference on Pharmaceutical Chemistry

April 24, 2022 | Seychelles

IIERD is aimed at providing a platform to discuss and enhance the developments in science, technology, management and allied areas to strengthen the core of research with new ideas to nurture.

1st Annual Psychedelic Therapeutics and Drug Development Conference

May 23-24, 2022 | USA

1st Annual Psychedelic Therapeutics and Drug Development Conference in 2021, we're thrilled to be hosting the 2nd Annual event on May 23-24, 2022 in Washington, DC.

DIGI-TECH PHARMA And AI 2022

May 10-11, 2022 | USA

The Digi-Tech Pharma & AI 2022 conference brings with it even more interactive sessions, expert speakers, senior professionals and decision makers from leading pharma, bio-tech and healthcare industry.

Spotlight

Each year lung cancer causes over 1.59 million deaths worldwide, more than any other cancer. Approximately 85% of lung cancer cases are a type of lung cancer called non-small cell lung cancer, and of these 5% are anaplastic lymphoma kinase (ALK)-positive. This type of lung cancer can be effectively targeted by a type of drug called an ALK-inhibitor, but how do they work?

resources